Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • Peer Navigation
Peer Support After Opioid Overdose: Randomized Trial Finds No Reduction in Future Adverse Events
Posted inEmergency Medicine news Psychiatry

Peer Support After Opioid Overdose: Randomized Trial Finds No Reduction in Future Adverse Events

Posted by MedXY By MedXY 02/11/2026
A randomized clinical trial of the Relay peer-navigator intervention in New York City found no significant reduction in opioid-related adverse events compared to standard care, despite high patient satisfaction and the intervention's grounding in evidence-based harm reduction principles.
Read More
  • Tuberculosis Post-Allogeneic Hematopoietic Stem Cell Transplantation in Low-Incidence Settings: Risk Factors, Clinical Trajectories, and Screening Mandates
  • Deciphering the Clinician’s Dilemma: Determinants of Antihypertensive Treatment Intensification in Older Adults
  • Targeting the Integrin αV-YAP-CTGF Axis: A New Frontier in Treating Congestive Hepatopathy and Liver Carcinogenesis
  • From Pressure to Cancer: Unveiling the Integrin αV-YAP-CTGF Axis as a Therapeutic Target in Congestive Hepatopathy
  • Nerandomilast Shows Potential Mortality Benefit in IPF Despite Neutral Composite Secondary Endpoints: Insights from FIBRONEER-IPF Extended Follow-up
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality nutrition obesity older adults oncology Pediatrics Physical Activity precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial SGLT2 inhibitors stroke targeted therapy type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in